Jeremy Teoh

MD (MBBS,FRCSEd (Urol), FCSHK, FHKAM (Surgery))

Dr Jeremy Teoh is currently the Assistant Dean (External Affairs) and Associate Professor of the Faculty of Medicine at the Chinese University of Hong Kong. He has primary interests in bladder cancer and prostate cancer. For bladder cancer, he is leading a multi-centre randomized controlled trial on transurethral en bloc resection of bladder tumour. He has also developed a global consensus statement to standardize the en bloc resection approach. He is currently studying the urinary biomarkers, tumour heterogeneity and molecular classification of bladder cancer. For prostate cancer, he has published extensively on the adverse events related to androgen deprivation therapy. He has also helped conduct a clinical trial on the use of the da Vinci Single-Port Surgical System in radical prostatectomy.

Jeremy was awarded the Ten Outstanding Young Persons Award (Hong Kong) and the SIU-Innovators Award in 2021. He has received numerous research grants with a total funding of more than HKD 80 million. He has published more than 200 articles in peer-reviewed journals such as Nature Reviews Urology, European Urology, Journal of Urology and Annals of Surgery. He is an editorial board member for a number of prominent journals, and he has been serving as a member for several advisory boards for prostate cancer and bladder cancer. Jeremy was the Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong (2019-2021), the Chair of the Young Fellows Chapter of the Hong Kong Academy of Medicine (2021-2022), and he has been the Director of the Lions Kidney Educational Centre & Research Foundation since 2016. He is also the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine.